8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Mar 23, 2026·SEC
Surrozen, Inc.(SRZN)Earnings, Financials & Key Ratios
SRZN•NASDAQ
Price updated Jun 19, 2026
AboutSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$3M-67.4%
- EBITDA-$42M-72.4%
- Net Income-$242M-280.8%
- EPS (Diluted)-32.37-49.4%
- Gross Margin84.56%-15.4%
- EBITDA Margin-1195.14%-428.5%
- Operating Margin-1210.58%-405.1%
- Net Margin-6960.77%-1066.8%
SRZN Key Insights
Surrozen, Inc. (SRZN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 49.3% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SRZN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SRZN Price & Volume
Surrozen, Inc. (SRZN) stock price & volume — 10-year historical chart
Loading chart...
SRZN Growth Metrics
Surrozen, Inc. (SRZN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-34.72%
TTM-35.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-319.27%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.97%
Return on Capital
10 Years-63.67%
5 Years-62.07%
3 Years-68.58%
Last Year-64.78%
SRZN Recent Earnings
Surrozen, Inc. (SRZN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$4.63-233.1%
$1.39
Rev
$5M+25.0%
$4M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$7.59-438.3%
$1.41
Rev
$514,000-22.2%
$661,000
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$3.61-208.5%
$1.17
Rev
$983,000
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.14+7.3%
$1.23
Rev
$983,000
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $4.63vs $1.39-233.1% | $5Mvs $4M+25.0% |
| Q2 2026 | Mar 23, 2026 | $7.59vs $1.41-438.3% | $514,000vs $661,000-22.2% |
| Q4 2025 | Nov 7, 2025 | $3.61vs $1.17-208.5% | $983,000 |
| Q3 2025 | Aug 8, 2025 | $1.14vs $1.23+7.3% | $983,000 |
Based on last 12 quarters of dataView full earnings history →
SRZN Peer Comparison
Surrozen, Inc. (SRZN) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare SRZN vs Peers
Surrozen, Inc. (SRZN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRZN Income Statement
Surrozen, Inc. (SRZN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 12.5M | 0 | 10.65M | 3.48M | 7.49M |
Revenue Growth % | - | - | - | - | -100% | - | -67.37% | -35.61% |
Cost of Goods Sold | 0 | 2.93M | 3.3M | 3.27M | 27.23M | 0 | 537K | 65K |
COGS % of Revenue | - | - | - | 26.15% | - | - | 15.44% | - |
Gross Profit | 0▲ 0% | -2.93M▲ 0% | -3.3M▼ 12.6% | 9.23M▲ 380.0% | -27.23M▼ 395.0% | 10.65M▲ 139.1% | 2.94M▼ 72.4% | 7.43M▲ 0% |
Gross Margin % | - | - | - | 73.85% | - | 100% | 84.56% | 99.13% |
Gross Profit Growth % | - | - | -12.56% | 379.98% | -394.98% | 139.13% | -72.41% | - |
Operating Expenses | 24.81M | 29.88M | 51.09M | 53.57M | 18.55M | 36.19M | 45.03M | 50.43M |
OpEx % of Revenue | - | - | - | 428.56% | - | 339.69% | 1295.14% | - |
Selling, General & Admin | 5.5M | 7.12M | 14.21M | 19.83M | 15.8M | 15.06M | 16.2M | 18.36M |
SG&A % of Revenue | - | - | - | 158.61% | - | 141.36% | 466.03% | - |
Research & Development | 19.6M | 25.68M | 36.88M | 37.01M | 27.23M | 21.13M | 29.36M | 32.13M |
R&D % of Revenue | - | - | - | 296.1% | - | 198.33% | 844.55% | - |
Other Operating Expenses | -300K | -2.93M | 0 | -3.27M | -24.48M | 0 | -537K | 0 |
Operating Income | -25.11M▲ 0% | -32.81M▼ 30.7% | -54.39M▼ 65.8% | -44.34M▲ 18.5% | -45.78M▼ 3.2% | -25.54M▲ 44.2% | -42.09M▼ 64.8% | -43M▲ 0% |
Operating Margin % | - | - | - | -354.71% | - | -239.69% | -1210.58% | -573.75% |
Operating Income Growth % | - | -30.67% | -65.79% | 18.48% | -3.25% | 44.21% | -64.81% | - |
EBITDA | -22.82M | -29.88M | -51.09M | -42.38M | -43.87M | -24.1M | -41.55M | -42.69M |
EBITDA Margin % | - | - | - | -339.07% | - | -226.16% | -1195.14% | -569.64% |
EBITDA Growth % | - | -30.91% | -71.01% | 17.05% | -3.5% | 45.07% | -72.45% | -73.42% |
D&A (Non-Cash Add-back) | 2.28M | 2.93M | 3.3M | 1.96M | 1.91M | 1.44M | 537K | 308K |
EBIT | -25.11M | -34.3M | -54.65M | -44.34M | -43.04M | -25.54M | -42.09M | -103.75M |
Net Interest Income | 444K | 91K | 72K | 781K | 2.34M | 1.69M | 3.02M | 3.64M |
Interest Income | 444K | 91K | 72K | 781K | 2.34M | 1.69M | 3.02M | 3.64M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 744K | 91K | -257K | 8.34M | 2.74M | -38.02M | -199.93M | -299.56M |
Pretax Income | -24.36M▲ 0% | -32.72M▼ 34.3% | -54.65M▼ 67.0% | -36M▲ 34.1% | -43.04M▼ 19.5% | -63.56M▼ 47.7% | -242.03M▼ 280.8% | -342.56M▲ 0% |
Pretax Margin % | - | - | - | -288.03% | - | -596.57% | -6960.77% | -4571.14% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -24.36M▲ 0% | -32.63M▼ 33.9% | -52.51M▼ 61.0% | -36M▲ 31.4% | -43.04M▼ 19.5% | -63.56M▼ 47.7% | -242.03M▼ 280.8% | -342.56M▲ 0% |
Net Margin % | - | - | - | -288.03% | - | -596.57% | -6960.77% | -4571.14% |
Net Income Growth % | - | -33.92% | -60.95% | 31.43% | -19.55% | -47.68% | -280.76% | -319.27% |
Net Income (Continuing) | -24.36M | -32.72M | -54.65M | -36M | -43.04M | -63.56M | -242.03M | -342.56M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -61.94▲ 0% | -41.12▲ 33.6% | -23.40▲ 43.1% | -15.55▲ 33.5% | -21.33▼ 37.2% | -21.67▼ 1.6% | -32.37▼ 49.4% | -31.29▲ 0% |
EPS Growth % | - | 33.61% | 43.09% | 33.55% | -37.17% | -1.59% | -49.38% | -68.97% |
EPS (Basic) | -61.94 | -41.12 | -23.40 | -15.55 | -21.33 | -21.67 | -32.37 | - |
Diluted Shares Outstanding | 393.31K | 795.6K | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M | 10.95M |
Basic Shares Outstanding | 393.31K | 795.6K | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M | 10.95M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SRZN Balance Sheet
Surrozen, Inc. (SRZN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 29.41M | 50.22M | 105.19M | 81.31M | 41.13M | 38.93M | 91.56M | 113.95M |
Cash & Short-Term Investments | 29.1M | 49.18M | 101.85M | 75.84M | 36.04M | 34.56M | 89.25M | 106.91M |
Cash Only | 29.1M | 34.98M | 33.09M | 24.69M | 36.04M | 34.56M | 89.25M | 106.91M |
Short-Term Investments | 0 | 14.2M | 68.76M | 51.15M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 1.98M | 2.15M | 2.54M | 208K | 5M |
Days Sales Outstanding | - | - | - | 57.76 | - | 87.05 | 21.83 | 125.96 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 756K | 580K | 671K | 2.11M | 2.04M |
Total Non-Current Assets | 13.07M | 11.84M | 31.98M | 8.13M | 4.95M | 9.54M | 7.17M | 6.76M |
Property, Plant & Equipment | 12.62M | 11.39M | 9.38M | 6.9M | 3.86M | 8.36M | 6.43M | 6.04M |
Fixed Asset Turnover | - | - | - | 1.81x | - | 1.27x | 0.54x | 1.15x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 21.66M | 0 | 688K | 0 | 688K | 688K |
Other Non-Current Assets | 454K | 444K | 954K | 1.23M | 402K | 1.17M | 46K | 722K |
Total Assets | 42.48M▲ 0% | 62.06M▲ 46.1% | 137.17M▲ 121.0% | 89.44M▼ 34.8% | 46.08M▼ 48.5% | 48.47M▲ 5.2% | 98.73M▲ 103.7% | 120.71M▲ 0% |
Asset Turnover | - | - | - | 0.14x | - | 0.22x | 0.04x | 0.07x |
Asset Growth % | - | 46.08% | 121.03% | -34.8% | -48.48% | 5.18% | 103.7% | 332.61% |
Total Current Liabilities | 3.9M | 7.28M | 13.57M | 9.73M | 7.15M | 7.32M | 9.93M | 9.56M |
Accounts Payable | 972K | 1.78M | 2.72M | 658K | 525K | 306K | 728K | 889K |
Days Payables Outstanding | - | 221.32 | 300.9 | 73.47 | 7.04 | - | 494.82 | 3.52K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.29M | 1.93M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 416K | 589K | 581K | 292K | 191K | 7.91M | 6.75M |
Current Ratio | 7.54x | 6.90x | 7.75x | 8.35x | 5.75x | 5.32x | 9.22x | 11.91x |
Quick Ratio | 7.54x | 6.90x | 7.75x | 8.35x | 5.75x | 5.32x | 9.22x | 11.91x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -3.4K |
Total Non-Current Liabilities | 9.2M | 7.49M | 13.9M | 3.7M | 997K | 62.53M | 276.56M | 389.29M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.85M |
Capital Lease Obligations | 9.2M | 7.49M | 5.6M | 3.38M | 882K | 6.64M | 5.35M | 12.15M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 8.3M | 326K | 115K | 55.89M | 271.21M | 384.44M |
Total Liabilities | 13.1M | 14.77M | 27.47M | 13.43M | 8.14M | 69.85M | 286.49M | 398.86M |
Total Debt | 10.7M | 9.6M | 7.79M | 5.6M | 3.38M | 8.47M | 6.64M | 6.78M |
Net Debt | -18.4M | -25.39M | -25.3M | -19.09M | -32.66M | -26.1M | -82.61M | -100.13M |
Debt / Equity | 0.36x | 0.20x | 0.07x | 0.07x | 0.09x | - | - | -0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.16x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 2.35x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 29.39M▲ 0% | 47.29M▲ 60.9% | 109.7M▲ 132.0% | 76M▼ 30.7% | 37.94M▼ 50.1% | -21.38M▼ 156.4% | -187.76M▼ 778.2% | -278.15M▲ 0% |
Equity Growth % | - | 60.94% | 131.96% | -30.72% | -50.09% | -156.36% | -778.21% | -5618.09% |
Book Value per Share | 74.71 | 59.44 | 46.97 | 32.83 | 18.80 | -7.29 | -25.11 | -25.40 |
Total Shareholders' Equity | 29.39M | 47.29M | 109.7M | 76M | 37.94M | -21.38M | -187.76M | -278.15M |
Common Stock | 1K | 2K | 4K | 0 | 0 | 0 | 1K | 1K |
Retained Earnings | -55.28M | -88M | -142.65M | -178.65M | -221.69M | -285.26M | -527.28M | -654.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -119K | -241K | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SRZN Cash Flow Statement
Surrozen, Inc. (SRZN) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -21.06M | -29.1M | -48.81M | -44.15M | -40.36M | -17.63M | -30.24M | -33.46M |
Operating CF Margin % | - | - | - | -353.16% | - | -165.44% | -869.83% | - |
Operating CF Growth % | - | -38.2% | -67.75% | 9.56% | 8.57% | 56.33% | -71.57% | -344.46% |
Net Income | -24.36M | -32.72M | -54.65M | -36M | -43.04M | -63.56M | -242.03M | -342.56M |
Depreciation & Amortization | 2.28M | 1.94M | 2.07M | 1.96M | 1.91M | 1.44M | 537K | 308K |
Stock-Based Compensation | 790K | 635K | 2.32M | 4.52M | 4.37M | 4.11M | 3.83M | 3M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.3M | 993K | 1.67M | -6.2M | 325K | 41.22M | 204.26M | 306.84M |
Working Capital Changes | -1.07M | 52K | -221K | -8.42M | -3.93M | -836K | 3.15M | -1.05M |
Change in Receivables | 0 | 0 | 0 | -1.98M | 0 | -502K | 2.33M | -2.71M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 537K | 857K | -2.04M | -133K | -228K | 142K | 307K |
Cash from Investing | -1.56M | -15.07M | -77.71M | 38.31M | 51.72M | -26K | -128K | -221K |
Capital Expenditures | -1.56M | -874K | -1.27M | -728K | -398K | -26K | -128K | -221K |
CapEx % of Revenue | - | - | - | 5.82% | - | 0.24% | 3.68% | 2.95% |
Acquisitions | 0 | 0 | 0 | -39.04M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 39.04M | 0 | 0 | 0 | 0 |
Cash from Financing | 28.9M | 50.05M | 124.63M | -2.56M | 276K | 16.18M | 85.05M | 38.95M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | -13K | 49.89M | 124.22M | -2.48M | -4K | 16.04M | 85.05M | 38.94M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -13K | 0 | 0 | -2.61M | -4K | 0 | 0 | 61K |
Other Financing | 28.92M | 166K | 410K | -85K | 280K | 133K | 0 | 9K |
Net Change in Cash | 29.51M▲ 0% | 5.88M▼ 80.1% | -1.89M▼ 132.2% | -8.4M▼ 344.3% | 11.64M▲ 238.5% | -1.48M▼ 112.7% | 54.68M▲ 3799.6% | 5.26M▲ 0% |
Free Cash Flow | -22.62M▲ 0% | -29.97M▼ 32.5% | -50.08M▼ 67.1% | -44.87M▲ 10.4% | -40.76M▲ 9.2% | -17.65M▲ 56.7% | -30.37M▼ 72.0% | -33.68M▲ 0% |
FCF Margin % | - | - | - | -358.98% | - | -165.69% | -873.51% | -449.44% |
FCF Growth % | - | -32.51% | -67.09% | 10.4% | 9.16% | 56.69% | -72.04% | -84.99% |
FCF per Share | -57.51 | -37.67 | -21.44 | -19.39 | -20.20 | -6.02 | -4.06 | -3.08 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.89x | 0.93x | 1.23x | 0.94x | 0.28x | 0.12x | 0.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SRZN Key Ratios
Surrozen, Inc. (SRZN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -85.09% | -66.89% | -38.78% | -75.55% | -767.91% | - | 309.79% |
Return on Invested Capital (ROIC) | -149.62% | -76.74% | -47.06% | -110.43% | - | - | 16.49% |
Gross Margin | - | - | 73.85% | - | 100% | 84.56% | 99.13% |
Net Margin | - | - | -288.03% | - | -596.57% | -6960.77% | -4571.14% |
Debt / Equity | 0.20x | 0.07x | 0.07x | 0.09x | - | - | -0.02x |
FCF Conversion | 0.89x | 0.93x | 1.23x | 0.94x | 0.28x | 0.12x | 0.10x |
Revenue Growth | - | - | - | -100% | - | -67.37% | -35.61% |
Related:SRZN Dividend History·SRZN Revenue History·SRZN Price History·SRZN P/E History·SRZN Financial Ratios·SRZN Institutional Holders
SRZN SEC Filings & Documents
Surrozen, Inc. (SRZN) SEC filings — annual & quarterly reports (10-K, 10-Q)
SRZN Frequently Asked Questions
Surrozen, Inc. (SRZN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Surrozen, Inc. (SRZN) reported $7.5M in revenue for fiscal year 2025.
Surrozen, Inc. (SRZN) saw revenue decline by 67.4% over the past year.
Surrozen, Inc. (SRZN) reported a net loss of $342.6M for fiscal year 2025.
Dividend & Returns
Surrozen, Inc. (SRZN) had negative free cash flow of $33.7M in fiscal year 2025, likely due to heavy capital investments.